As DoorDash gears towards its IPO, the food delivery app is set to join its competitors that are already publicly traded.
Airbnb bookings have dropped significantly during the coronavirus pandemic, with over 41% while the company is planning its IPO.
Zoom Communications has registered a phenomenal growth rate for the fiscal third-quarter reporting a net income of $198 and $777 revenue. Analysts have mixed views over the 12-month target for ZM stock.
Dow Jones, S&P 500, and Nasdaq Composite all surged between 10-12% during the month of November as markets remained upbeat on positive news of vaccine rollout. Analysts expect the market to continue its run ahead in December and end 2020 on a strong note.
Inking one of its biggest deals in history, Salesforce announced the acquisition of Slack for a massive $27 billion in a combination of stock and cash options. Salesforces said it will deeply integrate Slack as part of Salesforce Cloud and the Salesforce Customer 360 interface.
Pfizer and BioNTech applied for conditional marketing authorization (CMA) from the European Medicines Agency (EMA).
Nio has delivered 36,721 electric vehicles since the calendar flipped in January 2020. Hereby representing a rise of approximately 111.1% year-over-year.
The European stocks recovered significantly on the positive news about the COVID-19 vaccine as drugmakers gear up for mass production and distribution and await FDA approval. The Asia markets are looking positive as China’s growth picks up.
During the Q3 quarter that ended on October 31, Zoom recorded a revenue growth of 367% on an annualized basis in the quarter.
Kustomer allows businesses to interact with their customers through different channels.
The growth of Tesla is reflected in the surge in the company’s stock price. At the moment, Tesla is up 4% in the pre-market.
At present, all eyes are on coronavirus vaccine stocks. As a result, FAANG stocks are in the middle distance. However, this is temporary. According to Cramer, when the pandemic is over, it all will get back to normal.
On Monday, Moderna presented the latest report of its trials on a wide scale with a 94% efficacy rate as it awaits an FDA nod in the coming weeks soon to begin its vaccine rollout.
Nikola shares have been on a rollercoaster in the past few months. Today they have lost nearly 24% of their value.
Tesla applied for the Shanghai-made Model Y SUV sales permission earlier this month and got the permission to start sales.